Disruption of inflammatory signals by cytokine-targeted therapies for inflammatory bowel diseases
Open Access
- 1 August 2011
- journal article
- review article
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (4), 820-828
- https://doi.org/10.1111/j.1476-5381.2011.01614.x
Abstract
Gut inflammation occurring in patients with inflammatory bowel diseases (IBD) is associated with an excessive immune response that is directed against constituents of the normal bacterial flora and results in the production of large amounts of inflammatory cytokines. Anti‐cytokine compounds, such as the neutralizing TNF antibodies, have been employed with clinical success in patients with IBD. However, nearly half of IBD patients are refractory to such treatments, response can wane with time, and anti‐TNF treatment can associate with severe side effects and/or development/exacerbation of extra‐intestinal immune‐mediated pathologies. These observations, and the demonstration that, in IBD, the pathological process is also characterized by defects in the production and/or activity of counter‐regulatory cytokines, have boosted further studies aimed at delineating novel strategies to combat the IBD‐associated tissue‐damaging immune response.Keywords
This publication has 76 references indexed in Scilit:
- Aryl Hydrocarbon Receptor-Induced Signals Up-regulate IL-22 Production and Inhibit Inflammation in the Gastrointestinal TractGastroenterology, 2011
- Inflammatory Bowel DiseaseAnnual Review of Immunology, 2010
- Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 ReceptorNew England Journal of Medicine, 2009
- Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cellsGut, 2009
- Differences in binding and effector functions between classes of TNF antagonistsCytokine, 2009
- Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis or Psoriasiform ExanthemataAmerican Journal of Clinical Dermatology, 2008
- Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21Gut, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Transforming growth factor-β in T-cell biologyNature Reviews Immunology, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999